Subtopic Deep Dive
Epithelioid Hemangioendothelioma Clinical Outcomes
Research Guide
What is Epithelioid Hemangioendothelioma Clinical Outcomes?
Epithelioid hemangioendothelioma clinical outcomes refer to studies documenting survival rates, prognostic factors, and treatment responses for this rare vascular tumor across hepatic, pulmonary, and soft tissue sites.
Epithelioid hemangioendothelioma (EHE) exhibits a spectrum from indolent to aggressive behavior, with variable 5-year survival rates of 55-83% depending on site and risk factors (Deyrup et al., 2008; Mehrabi et al., 2006). Key papers include risk stratification models for soft tissue EHE (323 citations) and comprehensive reviews of hepatic EHE natural history (472 citations). Over 40 studies characterize outcomes with anti-angiogenic therapies like sorafenib showing partial responses in sarcomas including EHE (Maki et al., 2009, 569 citations).
Why It Matters
EHE's unpredictable progression impacts treatment decisions, with liver transplantation offering 83% 5-year survival for hepatic cases but uncertain benefits elsewhere (Mehrabi et al., 2006). Sorafenib demonstrated stable disease in 29% of advanced sarcoma patients including EHE subtypes, guiding anti-angiogenic trials (Maki et al., 2009). Risk stratification by size >10cm and multifocality predicts metastasis and mortality in soft tissue EHE, enabling personalized prognostication (Deyrup et al., 2008). These outcomes inform NCCN guidelines for rare vascular tumors, reducing overtreatment in indolent cases.
Key Research Challenges
Heterogeneous Clinical Behavior
EHE ranges from indolent to rapidly progressive, complicating prognosis across sites (Mehrabi et al., 2006). Hepatic cases show 55% 5-year survival with transplantation, while soft tissue multifocal tumors exceed 80% mortality (Deyrup et al., 2008). Standardized risk models remain elusive despite 49-case analyses.
Limited Therapeutic Evidence
Phase II sorafenib trials report only partial responses in 10-20% of sarcomas including EHE (Maki et al., 2009). No randomized data exist for anti-angiogenics or transplants beyond case series. Rarity hinders large-scale trials.
Site-Specific Prognostic Markers
Pulmonary EHE shows spontaneous regression in 14% but poor outcomes with metastases (Kitaichi et al., 1998). Soft tissue size >3cm and bone involvement predict aggression (Deyrup et al., 2008; Kleer et al., 1996). Unified markers across hepatic, pulmonary, and soft tissue sites are undefined.
Essential Papers
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · 2009 · Journal of Clinical Oncology · 569 citations
Purpose Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic s...
Angiosarcoma of skin and soft tissue: A study of forty-four cases
John C. Maddox, Harry L. Evans · 1981 · Cancer · 542 citations
Forty-four cases of skin and soft tissue angiosarcoma seen at M. D. Anderson Hospital before 1976 were reviewed. The cases fell into six different clinical groups: scalp-face, 17 cases; postmastect...
Primary malignant hepatic epithelioid hemangioendothelioma
Arianeb Mehrabi, Arash Kashfi, Hamidreza Fonouni et al. · 2006 · Cancer · 472 citations
Abstract Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with unknown etiology and a variable natural course. The authors present a comprehensi...
Cutaneous soft tissue sarcoma incidence patterns in the U.S.
Panta Rouhani, Christopher D.�M. Fletcher, Susan S. Devesa et al. · 2008 · Cancer · 337 citations
Abstract BACKGROUND. Cutaneous soft tissue sarcomas (CSTS) are a heterogeneous group of mesenchymal neoplasms. To the authors' knowledge, no prior large, population‐based study has focused on CSTS....
Epithelioid Hemangioendothelioma of Soft Tissue: A Proposal for Risk Stratification Based on 49 Cases
Andrea T. Deyrup, Mourad Tighiouart, Anthony Montag et al. · 2008 · The American Journal of Surgical Pathology · 323 citations
Epithelioid hemangioendothelioma (EHE) of soft tissue is a distinctive vascular tumor that has been variously considered a tumor of borderline malignancy and low-grade angiosarcoma. The majority of...
Congenital Nonprogressive Hemangioma
Paula E. North, Milton Waner, Charles A. James et al. · 2001 · Archives of Dermatology · 318 citations
Congenital nonprogressive hemangiomas are histologically and immunophenotypically distinct from classically presenting hemangiomas of infancy, unlikely to be related to the latter in pathogenesis.
Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor
Angela Sardaro, Lilia Bardoscia, Maria Fonte Petruzzelli et al. · 2014 · Oncology Reviews · 282 citations
Epithelioid hemangioendothelioma is a rare vascular tumor, described for the first time in 1975 by Dail and Liebow as an aggressive bronchoalveolar cell carcinoma. The etiology is still a dilemma. ...
Reading Guide
Foundational Papers
Start with Mehrabi et al. (2006, 472 citations) for hepatic EHE natural history and transplant outcomes; Deyrup et al. (2008, 323 citations) for soft tissue risk stratification; Maki et al. (2009, 569 citations) for sorafenib therapy evidence.
Recent Advances
Sardaro et al. (2014, 282 citations) updates EHE overview; Flucke et al. (2014, 257 citations) adds molecular genetics to 39 cases.
Core Methods
Risk models (size, multifocality); phase II trials (RECIST for sorafenib); Kaplan-Meier survival; WWTR1-CAMTA1 fusion detection (Deyrup 2008; Maki 2009; Flucke 2014).
How PapersFlow Helps You Research Epithelioid Hemangioendothelioma Clinical Outcomes
Discover & Search
Research Agent uses searchPapers and exaSearch to find 250+ EHE papers via OpenAlex, then citationGraph reveals Maki et al. (2009, 569 citations) as a sorafenib hub linking to 40 sarcoma trials. findSimilarPapers expands Deyrup et al. (2008) risk models to 50+ vascular tumor studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Mehrabi et al. (2006), then runPythonAnalysis with pandas computes pooled 5-year survival (e.g., 68% from 200 cases) and GRADE grades evidence as low-quality due to retrospective design. verifyResponse (CoVe) cross-checks sorafenib response rates against Maki et al. (2009) abstracts.
Synthesize & Write
Synthesis Agent detects gaps like absent pulmonary EHE transplant data via gap detection, flags contradictions between indolent hepatic vs. aggressive soft tissue outcomes. Writing Agent uses latexEditText, latexSyncCitations for Deyrup et al. (2008), and latexCompile to generate outcome tables; exportMermaid diagrams risk stratification flows.
Use Cases
"Run meta-analysis of 5-year survival rates for hepatic EHE from liver transplant studies"
Research Agent → searchPapers('hepatic epithelioid hemangioendothelioma transplant survival') → Analysis Agent → readPaperContent(Mehrabi 2006) + runPythonAnalysis(pandas meta-analysis on 472-cited data) → CSV export of pooled 83% survival with CI.
"Draft LaTeX review section on soft tissue EHE risk factors with citations"
Synthesis Agent → gap detection(Deyrup 2008) → Writing Agent → latexEditText('risk stratification') + latexSyncCitations(323-cited paper) + latexCompile → PDF section with size >10cm mortality table.
"Find code for EHE survival modeling from related sarcoma papers"
Research Agent → paperExtractUrls(Maki 2009) → paperFindGithubRepo → Code Discovery → githubRepoInspect(sorafenib response models) → Python sandbox with matplotlib Kaplan-Meier plots.
Automated Workflows
Deep Research workflow synthesizes 50+ EHE papers into structured report: searchPapers → citationGraph(Maki/Mehrabi hubs) → GRADE grading → exportBibtex. DeepScan's 7-step chain verifies sorafenib outcomes: readPaperContent → CoVe → runPythonAnalysis(trial response rates). Theorizer generates hypotheses on WWTR1-CAMTA1 fusions driving aggressive EHE from Flucke et al. (2014) molecular data.
Frequently Asked Questions
What defines epithelioid hemangioendothelioma clinical outcomes?
Clinical outcomes encompass survival, progression, and treatment responses for EHE across sites, with 5-year rates of 55-83% varying by multifocality and size (Deyrup et al., 2008; Mehrabi et al., 2006).
What methods assess EHE prognosis?
Risk stratification uses tumor size >10cm, multifocality, and mitotic rate; sorafenib phase II trials measure partial response and stable disease (Deyrup et al., 2008; Maki et al., 2009).
What are key papers on EHE outcomes?
Maki et al. (2009, 569 citations) on sorafenib in sarcomas; Mehrabi et al. (2006, 472 citations) on hepatic EHE transplants; Deyrup et al. (2008, 323 citations) on soft tissue risk models.
What open problems exist in EHE research?
Lack of randomized trials for anti-angiogenics, unified prognostic markers across sites, and predictors of spontaneous regression in pulmonary cases (Kitaichi et al., 1998; Maki et al., 2009).
Research Vascular Tumors and Angiosarcomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Epithelioid Hemangioendothelioma Clinical Outcomes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vascular Tumors and Angiosarcomas Research Guide